Trihexylphenedyl
- CAS NO.:144-11-6
- Empirical Formula: C20H31NO
- Molecular Weight: 301.47
- MDL number: MFCD00599600
- EINECS: 205-614-4
- SAFETY DATA SHEET (SDS)
- Update Date: 2024-10-24 21:11:45
What is Trihexylphenedyl?
Absorption
Trihexyphenidyl is absorbed from the gastrointestinal tract. Trihexyphenidyl reaches a Cmax of 7.2 ng/mL, with a Tmax of 1.3 hours, and an AUC of 201 ng*h/mL.
Toxicity
Symptoms of overdose include mydriasis, dryness of mucous membranes, red face, atonic states of bowels and bladder, and hyperthermia in high doses. Trihexyphenidyl causes agitation, confusion, and hallucinations due to its effects on the central nervous system. Untreated overdose may result in death, especially in children. Respiratory depression and cardiac arrest may be seen as premortal signs.
Patients experiencing an overdose of trihexyphenidyl may experience dry mouth, anhidrosis, mydriasis, nausea, vomiting, tachycardia, hyperpyrexia, reduced gastrointestinal motility, urinary hesitancy or retention, rash, hyperthermia, confusion, restlessness, agitation, poor coordination, paranoia, psychosis, delirium, hallucinations, coma, respiratory failure, circulatory failure, and death. Patients should be treated with symptomatic and supportive care which may include airway maintenance and the use of physostigmine.
Originator
Artane,Lederle,US,1949
The Uses of Trihexylphenedyl
Anticholinergic; antiparkinsonian.
The Uses of Trihexylphenedyl
Trihexyphenidyl, an antiparkinsonian drug, possesses central and peripheral anticholinergic actions, as well as a direct relaxant effect on smooth muscle. It reduces muscle rigidity and general stiffness, and has a relatively minor effect on tremors. It is used in Parkinsonism in the form of monotherapy as well as in combination with levodopa.
Indications
Tihexyphenidyl is indicated as an adjunct in the treatment of parkinsonism, an adjuvant in the treatment of parkinsonism with levodopa, and in the control of extrapyramidal disorders caused by central nervous system drugs.
Background
Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders. Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects. It has largely been replaced by drugs such as levodopa.
Trihexyphenidyl was granted FDA approval on 13 May 1949.
Definition
ChEBI: Trihexyphenidyl is an amine.
Manufacturing Process
Acetophenone, paraformaldehyde and piperidine are first reacted to give ω-(1-
piperidyl)propiophenone.
To an absolute ethyl ether solution of cyclohexylmagnesium bromide
(prepared from 261 parts of cyclohexyl bromide, 38.8 parts magnesium
turnings and 700 parts by volume absolute ethyl ether) a dry solution of 174
parts omega-(1-piperidyl)-propiophenonein 600 parts by volume of ether is
added, with stirring, at such a rate that gentle reflux is maintained with no
external cooling or heating. The reaction mixture is stirred for about 5 hours
and then allowed to stand at room temperature until reaction appears
complete. While being cooled the reaction mixture is then decomposed by the
dropwise addition of 500 parts by volume of 2.5 N hydrochloric acid, and
finally is made strongly acidic to Congo red by the addition of concentrated
hydrochloric acid.
The resulting white solid is collected on a filter, air dried, redissolved in 2,500
parts water at 95°C and the resulting solution treated with decolorizing
charcoal and clarified by filtration. The cooled filtrate is made alkaline with
ammonia and the product, crude 3-(1-piperidyl)-1-cyclohexyl-1-phenyl-1-
propanol is collected. The hydrochloride melts with decomposition in ten
seconds in a bath held at 258.5°C. The alcohol melts at 114.3° to 115.0°C,
according to US Patent 2,716,121.
brand name
Artane (Lederle); Tremin (Schering).
Therapeutic Function
Antiparkinsonian
Pharmacokinetics
Trihexyphenidyl is an antimuscarinic indicated as an adjunct in the treatment of parkinsonism or as a treatment for drug-induced extrapyramidal symptoms. It has a long duration of action as it does not need to be given every day. It has a wide therapeutic window, with acute toxicity being non fatal in doses as high as 300 mg. Patients should have their iridocorneal angle examined before and intraocular pressure monitored during therapy. Patients should be counselled regarding the risk of anhidrosis and hyperthermia.
Safety Profile
Poison by intraperitoneal, subcutaneous, and intravenous routes. When heated to decomposition it emits toxic fumes of NOx.
Synthesis
Trihexyphenidyl, 1-cyclohexyl-1-phenyl-3-piperidineopropan-1-ol (10.2.2), is synthesized by the reaction of 2-(1-piperidino)propiophenone (10.2.1) with cyclohexylmagnesiumbromide. The initial 2-(1-piperidino)propiophenone is synthesized in turn by the aminomethylation of benzophenone using paraformaldehyde and piperidine [24¨C27].
Metabolism
Data regarding the metabolism of trihexyphenidyl are not readily available. However, it is likely not heavily metabolized.
Properties of Trihexylphenedyl
Melting point: | 258.5°C |
Boiling point: | 442.59°C (rough estimate) |
Density | 0.9941 (rough estimate) |
refractive index | 1.5614 (estimate) |
pka | 14.31±0.29(Predicted) |
NIST Chemistry Reference | Trihexyphenidyl(144-11-6) |
Safety information for Trihexylphenedyl
Computed Descriptors for Trihexylphenedyl
Abamectin manufacturer
New Products
ALUMINIUM IODIDE 100 GM BUFFER CAPSULE PH 7.0 - 10 CAP BUFFER SOLUTION PH 9.5 (BORATE) EZEE BLUE GEL STAINER BORAX CARMINE (GRENACHERS ALCOHOLIC) POTASSIUM IODATE - IODIDE SOLN 0.1 N Dabigatran Acyl-O3-D-Glucuronide Trifluoroacetic Acid Salt Isofolic Acid Dabigatran 2-O-acylglucuronide metabolite Dabigatran Acyl-?-D- glucuronide Trifluroacetic Acid Erythromycin EP Impurity A Desloratidine Related Compound ARelated products of tetrahydrofuran
You may like
-
Dabigatran Acyl-O2-D-Glucuronide Trifluoroacetic Acid SaltView Details
-
Dechloro DesloratadineView Details
-
Dehydro DesloratadineView Details
-
Edoxaban Impurity 57View Details
2089454-69-1 -
Eltrombopag N-Oxide ImpurityView Details
2734533-17-4 -
Empagliflozin Bromo ImpurityView Details
-
Glycopyrronium Bromide EP Impurity IView Details
1404617-94-2 -
Ipratropium EP Impurity BView Details
58073-59-9